NCT04667104 - A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

May 16, 2022

Study Completion Date

April 17, 2023

Conditions

Hepatitis B, Chronic

Interventions

DRUG

JNJ-73763989

JNJ-73763989 injection will be administered subcutaneously once every 4 weeks.

DRUG

Tenofovir disoproxil

Tenofovir disoproxil film-coated tablet will be administered orally once daily.

DRUG

Tenofovir alafenamide (TAF)

TAF film-coated tablet will be administered orally once daily.

DRUG

Entecavir (ETV) monohydrate

ETV monohydrate film-coated tablet will be administered orally once daily.

DRUG

PegIFN-alpha2a

PegIFN-alpha2a injection will be administered subcutaneously once weekly.

Trial Locations (11)

704

National Cheng Kung University Hospital, Tainan City

807

Kaohsiung Medical University Hospital, Kaohsiung City

1010

New Zealand Clinical Research, Auckland

2025

Middlemore Clinical Trials, Papatoetoe

40447

China Medical University Hospital, Taichung

113 8519

Tokyo Medical and Dental University Hospital, Bunkyō City

565-0871

Osaka University Hospital, Suita-shi

80-462

Neutrum Lekarze M.Hlebowicz i Partnerzy spolka partnerska, Gdansk

41-400

ID Clinic, Mysłowice

01-201

Wojewodzki Szpital Zakazny w Warszawie, Warsaw

50 220

Przychodnia EuroMediCare Wroclaw Lowiecka, Wroclaw

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY